ARGENX SE
ARGX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ARGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARGX
ARGENX SE is a commercial-stage biotechnology company focused on developing and commercializing therapies for severe autoimmune diseases, anchored by its approved product VYVGART and a pipeline of late-stage candidates including efgartigimod and empasiprubart.
Key risk: Dependence on VYVGART sales
BioSniper Score
Based on 5 of 6 signals
Market Cap
$64.01B
Cash Runway
—
Lead Asset
Efgartigimod IV (Phase 2)
Next Catalyst
Phase3_Topline · Sep 30, 2026Financial data as of Dec 31, 2025.
Tracking 2 pipeline candidates · 53 clinical trials · 17 catalysts · 2 FDA decisions for ARGENX SE.
ARGENX SE is a commercial-stage biotechnology company focused on developing and commercializing therapies for severe autoimmune diseases, anchored by its approved product VYVGART and a pipeline of late-stage candidates including efgartigimod and empasiprubart.
- Product net sales of $4.2 billion for the year ended December 31, 2025 [sec · filed 2026-03-19].
- Cash and equivalents of $3,491.3M as of December 31, 2025 [sec].
- Net income of $1,292.0M for the year ended December 31, 2025 [sec].
- Shareholders' equity of $5,498.3M as of December 31, 2025 [sec].
- Total debt of $39.4M as of December 31, 2025 [sec].
- VYVGART surpassed $1 billion in product net sales in a single quarter for the first time in Q3 2025 [sec · filed 2026-03-19].
- As of December 31, 2025, the company had 1,863 full-time employees [sec · filed 2026-03-19].
What works
- VYVGART achieved over $1 billion in quarterly product net sales in Q3 2025, demonstrating strong commercial traction [sec · filed 2026-03-19].
- The company has a robust pipeline with 10 ongoing registrational clinical trials entering 2026, including Phase 3 programs for efgartigimod and empasiprubart [sec · filed 2026-03-19].
- A solid balance sheet with $3.5 billion in cash and equivalents provides financial flexibility to invest in pipeline and global expansion [sec].
- Successful launch of VYVGART Hytrulo pre-filled syringe in MG and CIDP expanded patient access and convenience [sec · filed 2026-03-19].
What to weigh
- The company's profitability is currently dependent on VYVGART sales, and it cannot assure sustained net profitability in the future [sec · filed 2026-03-19].
- Research and development expenses are expected to increase as the company advances multiple late-stage clinical programs, which could pressure margins [sec · filed 2026-03-19].
- The company faces risks related to clinical trial outcomes, regulatory approvals, and potential delays in pipeline programs [sec · filed 2026-03-19].
- If product net sales are insufficient or expenses are not controlled, the company may need to raise additional capital through equity or debt [sec · filed 2026-03-19].
From the filings
Quoted directly from source documents.
VYVGART surpassed $1 billion in quarterly product net sales in Q3 2025.
“the Company, with VYVGART surpassing $1 billion in product net sales in a single quarter for the first time in the third quarter of 2025.”
SEC filings · March 19, 2026
The company had 10 ongoing registrational clinical trials entering 2026.
“entering 2026 with 10 ongoing registrational clinical trials”
SEC filings · March 19, 2026
Product net sales were $4.2 billion for the year ended December 31, 2025.
“Product net sales of $4.2 billion”
SEC filings · March 19, 2026
The company had 1,863 full-time employees as of December 31, 2025.
“Expansion to 1,863 full-time employees (as of December 31, 2025)”
SEC filings · March 19, 2026
Catalyst timeline
- 2026-09-30 · Phase3_Topline — Phase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Ac — Topline data from a Phase 3 open-label study evaluating pharmacokinetics and safety of a candidate.
- 2026-10-15 · Phase2_Start — Phase 2 Start: A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and T — Initiation of a Phase 2 randomized placebo-controlled study to evaluate efficacy and safety.
- 2027-03-01 · Phase3_Topline — Phase 3 Topline: Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity o — Topline data from another Phase 3 open-label uncontrolled trial assessing pharmacokinetics and activity.
- 2027-12-01 · Phase3_Topline · efgartigimod — Phase 3 Topline: A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating th — Topline results from a Phase 3 randomized double-blind placebo-controlled study of efgartigimod.
- 2028-06-01 · Phase3_Topline · efgartigimod — Phase 3 Topline: A Randomized, Double-Blinded, Placebo-Controlled, Phase 3, Parallel-Group Design Study Evaluating th — Topline results from another Phase 3 randomized double-blind placebo-controlled study of efgartigimod.
- 2028-06-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study Followed — Topline data from a Phase 3 multicenter randomized double-blind placebo-controlled parallel-arm study.
- 2028-07-01 · Phase3_Topline — Phase 3 Topline: A Phase 3 Randomized, Double-Blinded, Placebo-Controlled Multicenter Trial With Open-Label Extension — Topline results from a Phase 3 randomized double-blind placebo-controlled multicenter trial with open-label extension.
- 2028-09-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the L — Topline data from a Phase 3 single-arm open-label extension study of a prior trial.
Risks & what to watch (4)›
Key risks
- Dependence on VYVGART sales — Profitability relies heavily on VYVGART; sustained net profitability not assured [sec · filed 2026-03-19].
- Clinical and regulatory uncertainty — Pipeline programs face risks of failed trials, ambiguous results, or regulatory delays [sec · filed 2026-03-19].
- Increasing R&D expenses — R&D costs expected to rise as late-stage programs advance, potentially impacting margins [sec · filed 2026-03-19].
- Need for additional capital — If sales are insufficient, the company may require equity or debt financing [sec · filed 2026-03-19].
What to watch
- Phase 3 topline results for efgartigimod in Myositis and ITP expected in 2026 [sec · filed 2026-03-19].
- Phase 3 clinical trials for empasiprubart in MMN and CIDP [sec · filed 2026-03-19].
- Regulatory submissions and approvals for VYVGART in new indications and geographies [sec · filed 2026-03-19].
- Commercial performance of VYVGART Hytrulo pre-filled syringe and expansion into new patient segments [sec · filed 2026-03-19].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run ARGENX SE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARGENX SE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 0.19
Lead: Phase 2
2 candidates
17 upcoming, next in ~31d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
472
Total value held
$16.57B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 5,083,464 | $3.70B |
| fmr llc | 4,991,034 | $3.64B |
| wellington management group llp | 1,021,457 | $745.9M |
| blackrock, inc. | 808,337 | $590.3M |
| rtw investments, lp | 709,446 | $518.1M |
| morgan stanley | 560,711 | $409.5M |
| alliancebernstein l.p. | 422,304 | $355.1M |
| bank of america corp /de/ | 400,117 | $292.2M |
| sands capital management, llc | 340,285 | $248.5M |
| bellevue group ag | 313,000 | $228.6M |
Showing top 10 of 472 institutional holders of ARGENX SE. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.3%
- Days to cover
- 6.8
- Shares short
- 2,077,333
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARGX short interestFrequently asked questions
What is the AI investment thesis for ARGENX SE?
ARGENX SE is a commercial-stage biotechnology company focused on developing and commercializing therapies for severe autoimmune diseases, anchored by its approved product VYVGART and a pipeline of late-stage candidates including efgartigimod and empasiprubart.
What is ARGENX SE's lead drug candidate?
ARGENX SE's most advanced tracked candidate is Efgartigimod IV (Phase 2) for Membranous Nephropathy; Lupus Nephritis; Immune Thrombocytopenia (ITP).
What is ARGENX SE's next catalyst?
ARGENX SE's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label, Uncontrolled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Ac" — expected September 30, 2026.
Who is the CEO of ARGENX SE?
Ms. Karen Massey is the chief executive officer of ARGENX SE (ARGX).
Where is ARGENX SE headquartered?
ARGENX SE (ARGX) is headquartered in Amsterdam, Netherlands.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.